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Initial DC targeting studies used the model antigens HEL and Ova
conjugated to anti-DEC-205 antibodies resulting in CD4 and CD8 T cellVaccination is one of the greatest success stories in medicine. responses inmurinemodels (Hawiger et al., 2001). Since then, amyriadEffective vaccines contain adjuvants that activate dendritic cells (DCs)
and of course the antigen(s), which are taken up by DCs and, after
processing into peptides, are presented on MHC molecules to activate
T cells. T cells are the backbone of adaptive immunity. Cytotoxic CD8 T
cells kill cells expressing peptides from intracellular microbial or
tumour antigens on MHC class I (MHC-I) molecules. CD4 T cells recog-
nise antigens derived from endocytosed antigens presented on surface
MHC-II molecules and respond by producing factors that help other
immune cells. Arguably the most important helper function is promot-
ing antibody production by B cells, but also CD8 T cells require help
from CD4 T cells. Importantly, before performing effector functions, T
cells ﬁrst must be activated by antigen-presenting cells, usually DCs.
DCs are crucial for activating CD8 T cells against endocytosed antigens,
by diverting them into specialised early endosomal compartments for
MHC-I presentation. This so-called cross-presentation is critical for
CD8 T cell responses against tumours, viral infections and all vaccina-
tions strategies (Kurts et al., 2010). In the current issue of EBioMedicine,
Yin et al. investigate strategies of antigen delivery for optimal cross-
presentation (Yin et al., 2016).
Many effective vaccines have been developed against a variety of
infections and tumour vaccination is currently receiving renewed inter-
est (Katsnelson, 2016). There have been extensive efforts in improving
vaccination strategies. Basic formulations consisting of antigen (peptide
or protein) with or without adjuvant elicit some T cell activation but
these are usually insufﬁcient to destroy established tumours (Mocellin
et al., 2004). Similarly, infusing patient-derivedDCs loadedwith tumour
antigens failed to broadly protect against malignomata, although T cell
responses were often observed (Anguille et al., 2014). Much research
has been focussed on improving T cell responses by targeting antigens
in vivo to speciﬁc receptors on DCs, mostly by coupling the antigen to
an antibody against a DC-speciﬁc cell surface molecule. The rationale
for this approach is two-fold: ﬁrst, DCs are targeted and thus antigen
is directed to those cells best able to activate T cells; and second, anti-
gen–antibody complexes are delivered to speciﬁc receptors on the DC
surface resulting in antigen trafﬁcking to MHC-I and/or MHC-IIom.2016.01.029.
rts@uni-bonn.de (C. Kurts).
. This is an open access article underof studies have targeted many different receptors and reported varying
degrees of CD4 and/or CD8 T cell activation (Kastenmüller et al., 2014).
This has been explained either by different DC subsets expressing
the receptor targeted or by different intracellular routing of antigen
initiated by the receptor targeted (Kurts et al., 2010). However, very
few studies have performed comparative studies on the efﬁciency of
different targeting antibodies with respect to activating CD4 and CD8
T cell responses (Kastenmüller et al., 2014).
In the present study by Yin et al., the authors quantitatively compare
the vaccination responses elicited by a panel of antigen-coupled
monoclonal antibodies against various human DC surface receptors
using polyI:C as adjuvant. For all antigen formulations tested, targeting
CD40 was most effective at inducing in vitro expansion of antigen-
speciﬁc CD8 T cells and acquisition of effector function. Targeting
antigen to CD40 resulted in a 3–4–fold increase in expansion of
antigen-speciﬁc CD8 T cells compared to OX-1 targeting, the second
best, and was about 1000× better than an equimolar amount of
uncoupled antigen. Similar results on CD40 targeting have been
reported before (Rosalia et al., 2015). However, the present study
identiﬁed a hierarchy of CD8 T cell priming efﬁciency depending on
the surface receptor targeted.
An open question for future studies is why targeting CD40 was
superior. Several explanations discussed by the authors are conceivable.
As previously described (Chatterjee et al., 2012), anti-CD40 Ig remains
mostly at the cell surface and trafﬁcs to early endosomes with little
delivery to late endolysosomes. The slow trafﬁcking of anti-CD40 Ig
compared to LOX-1 and Dectin-1 may explain why targeting CD40
resulted in prolonged antigen presentation to CD8 T cells. In addition,
antigen accumulation in early endosomes may be crucial for determin-
ing its superiority on cross-presentation (Kurts et al., 2010). A second
potential explanation may be the expression levels of CD40 on DCs,
which the authors propose to be somewhat higher than those of other
receptors used, e.g. LOX-1 and DEC-205. However, DCIR and CD40
were apparently expressed at similar levels and thus, at least for this
pair, expression levels cannot explain why CD40 targeting is superior.
A third explanation is that anti-CD40 Ig may activate DCs for better T
cell priming. However, the authors argue that targeting antigen with
anti-CD40 Ig in a previous report did not result in DC activation
(Chatterjee et al., 2012). However, Yin et al. used a different hybridomathe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
8 N. Garbi, C. Kurts / EBioMedicine 5 (2016) 7–8clone in the present study (12E12) and thus results are difﬁcult to ex-
trapolate. The authors argued that 12E12 did not activate DCs (data
not shown), but this possibility remains to be formally excluded. Future
studies are warranted to clarify the mechanisms underlying the superi-
ority of CD40 targeting.
What about CD4 T cell responses? Targeting CD40 was not as
efﬁcient as other receptors, possibly because CD40 does not recycle
into the late endosomal compartments, where MHC-II/peptide com-
plexes are mostly generated (Rocha and Neefjes, 2008). The ﬁnding
that some receptors are better suited for priming CD4 T cells and others
for CD8 T cells may not be surprising given the available literature
(Kastenmüller et al., 2014). However, the strength of the Yin et al.
study is the comprehensive comparative targeting of an ample set of
receptors.
In conclusion, Yin et al. suggest a hierarchy of DC receptor suitability
for promoting CD4 and/or CD8 T cell responses. As their study is based
primarily on human DCs expanded in vitro from blood-derived mono-
cytes, future work is warranted to extend these results to primary
human dendritic cells that activate T cells in response to vaccines. This
is challenging, but necessary as the CD40 expression proﬁles differ
between the murine and human system. The use of mice with a
humanised immune system may help to unveil such complexities,
facilitating rational design of optimal vaccines.
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